Abstract

Simple SummaryStore-operated calcium channels constituted from the proteins Orai and STIM are important targets for development of new drugs, especially for the treatment of auto-immune diseases. Also, interference with channel function is linked to reduced cancer cell progression, making these channels potential targets for anti-cancer drug development. Therefore, inhibitors need to be evaluated for both their binding selectivity and their potential to interfere with cancer progression. Here, we investigated the inhibitor Synta66 and determined its site of binding via both patch clamp recordings and computational approaches and evaluated its potency as anti-cancer agent in glioblastoma multiforme cells. Our findings show that Synta66 is a highly selective ligand to the Orai1 pore and efficiently blocks store operated calcium entry in glioblastoma cells. Still, in the tested cell lines, Synta66 did not reduce cell viability. We therefore suggest Synta66 as a precise tool to observe interference of store-operated Orai1 channel function in vitro and of resulting downstream effects.The Ca2+ sensor STIM1 and the Ca2+ channel Orai1 that form the store-operated Ca2+ (SOC) channel complex are key targets for drug development. Selective SOC inhibitors are currently undergoing clinical evaluation for the treatment of auto-immune and inflammatory responses and are also deemed promising anti-neoplastic agents since SOC channels are linked with enhanced cancer cell progression. Here, we describe an investigation of the site of binding of the selective inhibitor Synta66 to the SOC channel Orai1 using docking and molecular dynamics simulations, and live cell recordings. Synta66 binding was localized to the extracellular site close to the transmembrane (TM)1 and TM3 helices and the extracellular loop segments, which, importantly, are adjacent to the Orai1-selectivity filter. Synta66-sensitivity of the Orai1 pore was, in fact, diminished by both Orai1 mutations affecting Ca2+ selectivity and permeation of Na+ in the absence of Ca2+. Synta66 also efficiently blocked SOC in three glioblastoma cell lines but failed to interfere with cell viability, division and migration. These experiments provide new structural and functional insights into selective drug inhibition of the Orai1 Ca2+ channel by a high-affinity pore blocker.

Highlights

  • The Ca2+ channel protein complex formed by stromal interaction molecule (STIM) and Orai has been shown to mediate store-operated Ca2+ (SOC) influx in a large variety of cells including numerous cancer cell types

  • Patch clamp experiments with 1 μM Synta66 treatment upon maximum STIM1/Orai1 mediated currents resulted in slow inhibition (Figure S1A,B)

  • Previous results have shown that over-expressed STIM1/Orai1 currents were inhibited with an inhibitory concentration (IC50 ) of ∼4 μM and a Hill coefficient of ∼1 [40]

Read more

Summary

Introduction

The Ca2+ channel protein complex formed by stromal interaction molecule (STIM) and Orai has been shown to mediate store-operated Ca2+ (SOC) influx in a large variety of cells including numerous cancer cell types Under physiological conditions, this ubiquitous Ca2+ signalling pathway is activated by stimuli that deplete Ca2+ from endoplasmic reticulum (ER) stores [4,5,6,7], which is sensed by STIM1 and STIM2 via a luminally located.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call